Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 22687 [2014-09148]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 78 / Wednesday, April 23, 2014 / Notices
For Public
Toll Free Telephone: (800) 779–1088
Participant passcode: 4863751
Participant URL: https://
www.mymeetings.com/nc/join/
Purpose: The committee advises the
Secretary, Department of Health and Human
Services, and the Assistant Secretary for
Health in the (a) coordination of all research
and education programs and other activities
within the Department and with other
federal, state, local and private agencies, and
(b) establishment and maintenance of liaison
with appropriate private entities, federal
agencies, and state and local public health
agencies with respect to smoking and health
activities.
Matters For Discussion: The topic of the
meeting is ‘‘50 Years of U.S. Tobacco
Control’’ and will provide a review of the
recently released Surgeon General’s Report
on the Health Consequences of Smoking—50
Years of Progress—leading to a discussion of
what it will take to end the tobacco epidemic.
Agenda items are subject to change as
priorities dictate.
Contact Person For More Information:
Substantive program information as well as
summaries of the meeting and roster of
committee members may be obtained from
the internet at www.cdc.gov/tobacco in midAugust or from Ms. Monica L. Swann,
Management and Program Analyst, National
Center for Chronic Disease Prevention and
Health Promotion, CDC, 395 E. Street SW.,
Washington, DC 20024, telephone: (202) 245–
0552.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–09146 Filed 4–22–14; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
wreier-aviles on DSK5TPTVN1PROD with NOTICES
[FR Doc. 2014–09148 Filed 4–22–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0079]
Food and Drug Administration,
HHS.
ACTION:
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Conducting Public Health
Research in Thailand by the Ministry of
Public Health (MOPH), Funding
Opportunity Announcement (FOA)
GH11–002; Conducting Public Health
Research in China, FOA GH12–005,
initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
Jkt 232001
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
AGENCY:
Centers for Disease Control and
Prevention
15:37 Apr 22, 2014
Time and Date: 12:00 p.m.–5:00 p.m., May
14, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters For Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Conducting Public Health
Research in Thailand by the Ministry of
Public Health (MOPH), FOA GH11–002; and
Conducting Public Health Research in China,
FOA GH12–005, initial review.’’
Contact Person For More Information:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road, NE.,
Mailstop D–69, Atlanta, Georgia 30033,
Telephone: (404) 639–4796. The Director,
Management Analysis and Services Office,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Animal Generic
Drug User Fee Act Cover Sheet
BILLING CODE 4163–18–P
VerDate Mar<15>2010
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 23,
2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
SUMMARY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
22687
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0632. Also
include the FDA docket number found
in brackets in the heading of this
document.
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Form FDA 3728, Animal Generic Drug
User Fee Act Cover Sheet—21 U.S.C.
379j–21 (OMB Control Number 0910–
0632)—Revision
Section 741 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 379j–21) establishes three
different kinds of user fees: (1) Fees for
certain types of abbreviated applications
for generic new animal drugs, (2) annual
fees for certain generic new animal drug
products, and (3) annual fees for certain
sponsors of abbreviated applications for
generic new animal drugs and/or
investigational submissions for generic
new animal drugs (21 U.S.C. 379j–
21(a)). Because concurrent submission
of user fees with applications is
required, the review of an application
cannot begin until the fee is submitted.
Form FDA 3728 is the Animal Generic
Drug User Fee Act (AGDUFA) Cover
Sheet, which is designed to provide the
minimum necessary information to
determine whether a fee is required for
review of an application, to determine
the amount of the fee required, and to
account for and track user fees.
The Animal Generic Drug User Fee
Amendments of 2013, signed by the
President on June 13, 2013 (AGDUFA II)
(Title II of Pub. L. 113–14), amended the
FD&C Act authorizing FDA to collect
user fees for certain abbreviated
applications for generic new animal
drugs, for certain generic new animal
drug products, and for certain sponsors
of such abbreviated applications for
generic new animal drugs and/or
investigational submissions for generic
new animal drugs. To implement
changes under the reauthorization by
their effective date of October 1, 2013,
FDA sought and received OMB approval
to update its Form FDA 3728 as
described as follows:
E:\FR\FM\23APN1.SGM
23APN1
]]>Agencies
[Federal Register Volume 79, Number 78 (Wednesday, April 23, 2014)]
[Notices]
[Page 22687]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09148]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Conducting Public Health
Research in Thailand by the Ministry of Public Health (MOPH), Funding
Opportunity Announcement (FOA) GH11-002; Conducting Public Health
Research in China, FOA GH12-005, initial review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Date: 12:00 p.m.-5:00 p.m., May 14, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters For Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``Conducting Public Health Research in Thailand by the
Ministry of Public Health (MOPH), FOA GH11-002; and Conducting
Public Health Research in China, FOA GH12-005, initial review.''
Contact Person For More Information: Hylan Shoob, Scientific
Review Officer, Center for Global Health (CGH) Science Office, CGH,
CDC, 1600 Clifton Road, NE., Mailstop D-69, Atlanta, Georgia 30033,
Telephone: (404) 639-4796. The Director, Management Analysis and
Services Office, has been delegated the authority to sign Federal
Register notices pertaining to announcements of meetings and other
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and
Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2014-09148 Filed 4-22-14; 8:45 am]
BILLING CODE 4163-18-P
